A preliminary gene expression profile of acute graft-versus-host disease
A preliminary gene expression profile of acute graft-versus-host disease
复制标题
DOI：
10.3727/096368908785096042
复制
发表时间：
2008-01-01
影响因子：
3.3
通讯作者：
Reddy, Vijay
中科院分区：
文献类型：
--
作者：
Buzzeo, Matthew P.;Yang, Jie;Reddy, Vijay
异基因造血干细胞移植（HSCT）是治疗高危恶性血液病的首选方法，但与此治疗相关的主要并发症是急性移植物抗宿主病（GVHD）。尽管有明确的病理生理学机制，但没有明确的标志物用于预测急性GVHD发展或进展到晚期。在本研究中，我们招募了4名急性GVHD和4名急性GVHD无同种异体HSCT受者，并在临床急性GVHD发作前采集外周血，用于在AffyphineGeneChip @ Human Genome U133 Plus 2.0微阵列上进行分析。根据移植类型的协方差分析（ANCOVA）、合并误差估计和10%的错误发现率（FDR），我们注意到对照组和急性GVHD患者之间1,658个基因的表达存在显著差异。总之，我们提供了第一份报告的初步分子标记的急性移植物抗宿主病异基因造血干细胞移植患者。
Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for high-risk hematological malignancies, yet a major complication associated with this therapy is acute graft-versus-host disease (GVHD). Despite a well-defined pathophysiological mechanism, there are no definitive markers for.predicting acute GVHD development or progression to advanced stages. In the current study, we enrolled four acute GVHD and four acute GVHD-free recipients of allogeneic HSCT and collected peripheral blood just prior to onset of clinical acute GVHD for analysis on Affymetrix GeneChip@ Human Genome U133 Plus 2.0 microarrays. We noted significant differences in expression of 1,658 genes between control and acute GVHD patients, based on an analysis of covariance (ANCOVA) by type of transplant, a pooled error estimate, and a false discovery rate (FDR) of 10%. In conclusion, we offer the first report of a preliminary molecular signature of acute GVHD in allogeneic HSCT patients.